MAXIMIZING SUCCESS IN RARE DISEASE STUDIES: KEY DRIVERS AND INSIGHTS.

The article presents an interview with Sanjay Shukla, Chief executive officer of aTyr Pharma, about the company's clinical operations and ongoing Phase III study for pulmonary sarcoidosis. He discusses the challenges of conducting a large trial for a rare disease and how aTyr Pharma is overcoming them. He highlights the importance of incorporating patient feedback into the trial design and the significant role it plays in competitiveness and commercialization success.